Search Results - "Ahn, Linda S"

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas by Elkrief, Arielle, Makhnin, Alex, Moses, Khadeja A, Ahn, Linda S, Preeshagul, Isabel R, Iqbal, Afsheen N, Hayes, Sara A, Plodkowski, Andrew J, Paik, Paul K, Ladanyi, Marc, Kris, Mark G, Riely, Gregory J, Michor, Franziska, Yu, Helena A

“…Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR…”
Get full text

Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor) by de Camargo, Veridiana Pires, Keohan, Mary L., D'Adamo, David R., Antonescu, Cristina R., Brennan, Murray F., Singer, Samuel, Ahn, Linda S., Maki, Robert G.

“…BACKGROUND: In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to…”
Get full text

Pilot Study of Dacomitinib for Patients With Metastatic EGFR -Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib by Choudhury, Noura J, Makhnin, Alex, Tobi, Yosef Y, Daly, Robert M, Preeshagul, Isabel R, Iqbal, Afsheen N, Ahn, Linda S, Hayes, Sara A, Heller, Glenn, Kris, Mark G, Riely, Gregory J, Yu, Helena A

“…Patients with mutant lung cancer have no approved targeted therapies after disease progression on first-line osimertinib, a third-generation epidermal growth…”
Get more information

Clinical outcomes of systemic therapy for patients with deep fibromatoses (desmoid tumors) by de Camargo, Veridiana Pires, Keohan, Mary L., D’Adamo, David R., Antonescu, Cristina R., Brennan, Murray F., Singer, Samuel, Ahn, Linda S., Maki, Robert G.

Get full text